The National Institute on Aging is offering a grant for Early-Stage T1 Translational Aging Research to develop novel therapeutics targeting conditions related to aging in older individuals. This grant supports the translation of discoveries into pharmacological strategies, natural products, biologics, and stem cell therapies for conditions like sarcopenia, heart failure, immunosenescence, and metabolic syndrome. Applications should focus on innovative treatment targets and approaches. The closing date for this grant opportunity is July 16, 2022.
Opportunity ID: 317505
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-19-304 |
| Funding Opportunity Title: | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 25, 2019 |
| Last Updated Date: | Jun 25, 2019 |
| Original Closing Date for Applications: | Jul 16, 2022 |
| Current Closing Date for Applications: | Jul 16, 2022 |
| Archive Date: | Aug 21, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Small businesses Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities City or township governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Private institutions of higher education County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasisand autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-19-304.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 317505 Full Announcement-PAR-19-304 -> PAR-19-304-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00252332 | Sep 16, 2019 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00260065 | Sep 16, 2019 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00272087 | Feb 16, 2022 | Jul 16, 2022 | View |
Package 1
Mandatory forms
317505 RR_SF424_2_0-2.0.pdf
317505 PHS398_CoverPageSupplement_4_0-4.0.pdf
317505 RR_OtherProjectInfo_1_4-1.4.pdf
317505 PerformanceSite_2_0-2.0.pdf
317505 RR_KeyPersonExpanded_2_0-2.0.pdf
317505 RR_Budget_1_4-1.4.pdf
317505 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
317505 RR_SubawardBudget30_1_4-1.4.pdf
317505 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
317505 RR_SF424_2_0-2.0.pdf
317505 PHS398_CoverPageSupplement_5_0-5.0.pdf
317505 RR_OtherProjectInfo_1_4-1.4.pdf
317505 PerformanceSite_2_0-2.0.pdf
317505 RR_KeyPersonExpanded_2_0-2.0.pdf
317505 RR_Budget_1_4-1.4.pdf
317505 PHS398_ResearchPlan_4_0-4.0.pdf
317505 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
317505 RR_SubawardBudget30_1_4-1.4.pdf
317505 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
317505 RR_SF424_5_0-5.0.pdf
317505 PHS398_CoverPageSupplement_5_0-5.0.pdf
317505 RR_OtherProjectInfo_1_4-1.4.pdf
317505 PerformanceSite_4_0-4.0.pdf
317505 RR_KeyPersonExpanded_4_0-4.0.pdf
317505 RR_Budget_3_0-3.0.pdf
317505 PHS398_ResearchPlan_4_0-4.0.pdf
317505 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
317505 RR_SubawardBudget30_3_0-3.0.pdf
317505 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
